Australia seems poised to welcome a groundbreaking therapy for weight issues: Retatrutide. The dual molecule – acting on both GLP-1 and GIP receptors – demonstrates significant outcomes in international trials, pointing to substantial decreases in weight. While regulatory clearance hasn't occurred with the Therapeutic Goods Administration (TGA)